The cardiovascular event reduction tool (CERT) - A simplified cardiac risk prediction model developed from the West of Scotland Coronary Prevention Study (WOSCOPS)

American Journal of Cardiology

Volumn 85, Issue 6, 2000, Pages 720-724

  L'Italien, Gilbert ^a   Ford, Ian ^b   Norrie, John ^b   Lapuerta, Pablo ^a   Ehreth, Jenifer ^a   Jackson, Joseph ^a   Shepherd, James ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; PLACEBO; PRAVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MODEL; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING;

AGE FACTORS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY DISEASE; HUMANS; MALE; MIDDLE AGED; PRAVASTATIN; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SCOTLAND;

EID: 0034654457     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00847-4     Document Type: Article

References (13)

1. Wilson P.W.F., D'Agostino Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation. 97:1998;1837-1847.
2. Anderson K.M., Wilson P.W.F., Odell P.M., Kannel W.B. An updated coronary risk profile a statement for health professionals . Circulation. 83:1991;357-363.
3. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention trial. Circulation. 97:1998;1440-1445.
4. Fager G. Cholesterol reduction and clinical benefit. Are there limits to our expectations? Arterioscler Thromb Vasc Biol. 17:1997;3527-3533.
5. Greenland P., Grundy S., Pasternak R.C., Lenfant C. Problems on the pathway from risk assessment to risk reduction. Circulation. 97:1998;1761-1762.
6. Muldoon F.H., Criqui M.H. The emerging role of statins in the prevention of coronary heart disease. Statins are effective but we need better ways of assessing risk. BMJ. 315:1997;1554-1555.
7. A coronary primary prevention study of scottish men aged 45-64 years. Trial design. J Clin Epidemiol. 34:1992;849-860.
8. Collett D. Modeling Survival Data in Medical Research. 1994;Chapman and Hall, London.
9. Baseline risk factors and their association with outcome in the west of Scotland coronary prevention study. Am J Cardiol. 79:1997;756-762.
10. U.S. Department of Health and Human Services (DHHS). National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994. Hyattsville, MD: Centers for Disease Control and Prevention, 1996.
11. Kinosian B., Glick H., Garland G. Cholesterol and coronary heart disease predicting risk by levels and ratios . Ann Intern Med. 121:1994;641-647.
12. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Gotto AM. Air Force/Texas Coronary Atherosclerosis Prevention Study: primary prevention of coronary heart disease in women. Circulation 1998;98(suppl. 17):I-46.
13. Alvins A.L., Browner W.S. Improving prediction of coronary heart disease to aid the management of high cholesterol levels. What a difference a decade makes. JAMA. 279:1998;445-449.